Remove Bicuspid/Mitral Remove Stenosis Remove TAVR
article thumbnail

TAVR Found Non-Inferior to SAVR for Low-Risk Patients

DAIC

TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. The DEDICATE-DZHK6 trial compared TAVR vs. SAVR in 1,414 patients who underwent valve replacement procedures at 38 centers in Germany.

TAVR 111
article thumbnail

New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

DAIC

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%

TAVR 111
article thumbnail

SAVR’s Value in the TAVR Era

CardiacWire

Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.

TAVR 69
article thumbnail

Cover Story | Clinical Decision-Making in Aortic Stenosis in Patients With Bicuspid Valves

American College of Cardiology

has seen a 25-fold increase in the use of TAVR, with more than 100,000 performed annually. In the past decade, the U.S. This technique is now employed in approximately 85% of all isolated aortic valve replacements. Despite this growth, there are notable gaps in the evidence.

article thumbnail

Transcatheter versus surgical valve replacement in patients with bicuspid aortic valves: an updated meta-analysis

The British Journal of Cardiology

Patients with bicuspid aortic valves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. to 4.58, p=0.04).

article thumbnail

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Open Heart

Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aortic stenosis (AS) prior to transcatheter aortic valve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. after TAVR, were available from 247 patients (67.5%). ±15.8 ±15.1

article thumbnail

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

CardiacWire

These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways… JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notable given that all other TAVR systems only address aortic stenosis.